摘要
O型异戊二烯基次级代谢产物(3,3-二甲基烯丙基,香叶基,法尼基和相关的生物合成的衍生物)代表一类很少存在的天然产物。 在过去的二十年中这样的化合物已经被发现有希望的有效药理活性,尤其在抗癌特性方面。迄今约350氧异戊烯基次生代谢产物, 在大多数情况下,其中有一个苯丙或聚酮的核心,主要被提取的植物是属于芸香科,伞形科和豆科,还有从真菌和细菌。这篇综 合性的综述目的是做一个调查关于到目前为止的文献报道中,O型异戊二烯基二次代谢产物体现在体内和体外抗癌特性于植物化学 和药理学方面的观点。
关键词: 蒽醌类,癌症,查耳酮,肉桂酸,香豆素,二酮哌嗪,氧异戊烯基次级代谢产物
Current Medicinal Chemistry
Title:A Novel Class of Emerging Anticancer Compounds: Oxyprenylated Secondary Metabolites from Plants and Fungi
Volume: 22 Issue: 30
Author(s): Salvatore Genovese, Serena Fiorito, Francesco Epifano and Vito Alessandro Taddeo
Affiliation:
关键词: 蒽醌类,癌症,查耳酮,肉桂酸,香豆素,二酮哌嗪,氧异戊烯基次级代谢产物
摘要: O-Prenyl secondary metabolites (3,3-dimethylallyl, geranyl-, farnesyl- and related biosynthetic derivatives) represent a class of rarely occurring natural products. In the last two decades such compounds have been found to exert promising and effective pharmacological activities, mainly in terms of anti-cancer properties. To date about 350 oxyprenylated secondary metabolites, the most part of which having a phenylpropanoid or a polyketide core, have been extracted from plants mainly belonging to the Rutaceae, Apiaceae, and Fabaceae families, and from fungi and bacteria. The aim of this comprehensive review is to make a survey of the in so far reported literature citations about O-prenyl secondary metabolites exhibiting in vitro and in vivo anti-cancer properties from phytochemical and pharmacological point of views.
Export Options
About this article
Cite this article as:
Salvatore Genovese, Serena Fiorito, Francesco Epifano and Vito Alessandro Taddeo , A Novel Class of Emerging Anticancer Compounds: Oxyprenylated Secondary Metabolites from Plants and Fungi, Current Medicinal Chemistry 2015; 22 (30) . https://dx.doi.org/10.2174/0929867322666150716114758
DOI https://dx.doi.org/10.2174/0929867322666150716114758 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Recent Development of Copolymeric Nano-Drug Delivery System for Paclitaxel
Anti-Cancer Agents in Medicinal Chemistry Privileged Scaffolds Targeting Bromodomain-containing Protein 4
Current Topics in Medicinal Chemistry Potential Roles of Eosinophils in Cancer Therapy: Epidemiological Studies, Experimental Models, and Clinical Pathology
Recent Patents on Anti-Cancer Drug Discovery In-Situ Hybridization as a Molecular Tool in Cancer Diagnosis and Treatment
Current Medicinal Chemistry Orally Administrated Small Molecule Drugs with Intestine Targeted Profile: Recent Development and Prospects
Current Medicinal Chemistry Effect of Lapachol on the Inhibition of Matrix Metalloproteinase Related to the Invasion of Human Fibrosarcoma Cells
Current Molecular Pharmacology Protein Kinases as Drug Targets in Human and Animal Diseases
Current Enzyme Inhibition Epidermal Cell Proliferation in Calorie-Restricted Aging Rats
Current Aging Science Sphingolipids in Cell Signaling: Their Function as Receptor Ligands, Second Messengers, and Raft Constituents
Current Immunology Reviews (Discontinued) Small and Long Non-Coding RNAs: Novel Targets in Perspective Cancer Therapy
Current Genomics Glatiramer Acetate Induced Hepatotoxicity
Current Drug Safety An Overview of Phytotherapeutic Approaches for the Treatment of Benign Prostatic Hyperplasia
Mini-Reviews in Medicinal Chemistry Understanding Tumor-Antigen Presentation in the New Era of Cancer Immunotherapy
Current Pharmaceutical Design Targeting Histone Deacetylases for the Treatment of Immune, Endocrine & Metabolic Disorders
Endocrine, Metabolic & Immune Disorders - Drug Targets Therapeutic Potential of Targeting Transforming Growth Factor-beta in Colorectal Cancer: Rational and Progress
Current Pharmaceutical Design Occupational Risk Assessment of Engineered Nanomaterials: Limits, Challenges and Opportunities
Current Nanoscience Monoclonal Antibodies Carried in Drug Delivery Nanosystems as a Strategy for Cancer Treatment
Current Medicinal Chemistry Emerging Strategies to Strengthen the Anti-Tumour Activity of Type I Interferons: Overcoming Survival Pathways
Current Cancer Drug Targets Small Molecules with EGFR-TK Inhibitor Activity
Current Drug Targets Decoding the Knots of Initiation of Oncogenic Epithelial-Mesenchymal Transition in Tumor Progression
Current Cancer Drug Targets